Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

Summary

The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes

Timeline

Start

2010-03

Primary completion

2010-12

Completion

2011-03

Outcome

Met primary endpoint

paper 0.13 (95% CI, 0.04 to 0.38) with the 75-mg daily dose PMID 24428466 ↗

Publications

• Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014 Jan 16;370(3):201-10. doi: 10.1056/NEJMoa1301150.

Drugs

Indications